No Data
Optimism Over Global Healthcare Sector Rises: Jefferies
ImmunityBio And NCartes Enter Collaboration Agreement Aimed At Automating And Streamlining The Data Fulfillment Process For Clinical Trials; The Goal Of The Collaboration Is To Make This Essential Process Easier, Faster, And Less Expensive For...
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment Of The 100th Patient In BCG Unresponsive NMIBC CIS Trial And Reports A Complete Response Rate Of 71% With A Durable Duration Of Response Ranging Up To 54 Months Reported For 82 Patients...
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket